AlloVir Revenue and Competitors
Estimated Revenue & Valuation
- AlloVir's estimated annual revenue is currently $22.6M per year.
- AlloVir's estimated revenue per employee is $174,077
- AlloVir's total funding is $159M.
- AlloVir's current valuation is $677.5M. (January 2022)
Employee Data
- AlloVir has 130 Employees.
- AlloVir grew their employee count by -4% last year.
AlloVir Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $7M | 45 | 73% | N/A | N/A |
#10 | $5.4M | 35 | 3% | N/A | N/A |
What Is AlloVir?
AlloVir, formerly ViraCyte, was founded in 2013 and is the leader in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The companyￃﾢ￢ﾂﾬ￢ﾄﾢs technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. AlloVirￃﾢ￢ﾂﾬ￢ﾄﾢs technology and manufacturing process enables the potential for the treatment and/or prevention of up to six devastating viruses with each single allogeneic cell therapy. The company is advancing multiple mid- and late-stage clinical trials across its product portfolio.
keywords:N/A
$159M
Total Funding
130
Number of Employees
$22.6M
Revenue (est)
-4%
Employee Growth %
$677.5M
Valuation
N/A
Accelerator
AlloVir's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Executive Director | Reveal Email/Phone |
2 | N/A | Reveal Email/Phone |
3 | Clinical Operations Manager | Reveal Email/Phone |
4 | SVP Business Development | Reveal Email/Phone |
5 | Senior Manager, Process Data Systems and Analytics | Reveal Email/Phone |
6 | SVP, Global Regulatory Affairs | Reveal Email/Phone |
7 | Director, Supplier & Quality Systems Mgmt and Compliance | Reveal Email/Phone |
8 | Director, External Manufacturing | Reveal Email/Phone |
9 | VP - Quality Operations | Reveal Email/Phone |
10 | Executive Assistant To CEO | Reveal Email/Phone |
AlloVir News
AlloVir's lead product, posoleucel, is in late-stage clinical development as an allogeneic, off-the-shelf, multi-virus specific T cell...
AlloVir, a late clinical-stage allogeneic T cell immunotherapy company, announced Wednesday that it has received an FDA RMAT designation for...
AlloVir Inc. shares rose 21% to $6.53 premarket after the company said the U.S. Food and Drug Administration granted regenerative medicine...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar 22, 2021-- AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, announced today that its Board of Directors has appointed Diana M. Brainard, M.D., as the company’s Chief Executive Officer (CEO), effective May 17, 2021. Dr. Brainard has serve ...
Based in Houston, AlloVir is developing allogeneic cell therapies for viral diseases and is planning Phase III studies for its lead product candidate, Viralym-M, within the next 12 months. The cell therapy is being developed for six viruses commonly found in patients with compromised immune syst ...
Other Companies in Cambridge
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $16.9M | 130 | -8% | $119.7M |
#2 | $45.9M | 130 | 69% | N/A |
#3 | $31.8M | 131 | -3% | $10.8M |
#4 | $13.4M | 131 | 10% | N/A |
#5 | $7.5M | 131 | -13% | N/A |